Arbele, a Hong Kong-based biotechnology company focused on developing innovative targeted cancer therapies, announced on Wednesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for ARB1002, its investigational antibody-drug conjugate (ADC) for the treatment of pancreatic cancer.
ARB1002 is composed of an anti-CDH17 monoclonal antibody chemically linked to a potent cytotoxic agent. The ADC is designed to selectively bind CDH17, a cell-surface adhesion molecule overexpressed in pancreatic cancer, enabling targeted delivery of the cytotoxic payload to tumour cells while limiting off-target exposure.
ARB1002 is planned to enter a Phase 1 clinical trial this year, with Arbele completing IND-enabling studies to support its clinical assessment in pancreatic cancer.
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
Organon signs commercialisation agreement for Nilemdo across six European markets
Antin to acquire clinical trial equipment provider Emsere
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Eli Lilly agrees to acquire Ventyx Biosciences
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens